# Nimotuzumab or placebo with radiotherapy for high-grade glioma: a Cuban randomised double-blind trial

Source: https://onco.cc/key-papers/paper-solomon-nimotuzumab-high-grade-glioma-bmc-cancer-2013/  
OnCo record `paper-solomon-nimotuzumab-high-grade-glioma-bmc-cancer-2013` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In 70 Cuban patients with high-grade glioma, adding the anti-EGFR antibody nimotuzumab to radiotherapy gave a median survival of 17.8 months against 12.6 months with placebo. The abstract's background says the antibody does not cause the skin toxicity of other anti-EGFR antibodies; that is not reported as a result of this trial.

## Summary

A randomised, double-blind, multicentre trial in 41 patients with anaplastic astrocytoma and 29 with glioblastoma, who received radiotherapy with six weekly doses of 200 mg nimotuzumab or placebo, then maintenance every three weeks for a year. The trial is registered in the Cuban National Register for clinical trials (No. 1745).

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: BMC Cancer
- Year: 2013
- DOI: 10.1186/1471-2407-13-299
- Authors: Solomón MT, Selva JC, Figueredo J, et al.
- Findings: Median survival was 17.76 months with nimotuzumab and 12.63 months with placebo; mean survival 31.06 against 21.07 months.; The median cumulative dose was 3,200 mg over a median of 16 doses.; The commonest related adverse reactions were nausea, fever, tremors, anorexia and altered liver tests; no anti-idiotypic antibody response was detected.
- What it means: A small randomised trial of nimotuzumab with radiotherapy for high-grade glioma. Cuba's regulator CECMED lists adult high-grade glioma with radiotherapy among the indications of CIMAher (nimotuzumab), registered there since 19 February 2002.
- Caveats: Small trial mixing two tumour types.; The abstract reports medians without a hazard ratio or confidence interval.

## Sources

- BMC Cancer 2013: https://doi.org/10.1186/1471-2407-13-299
- PubMed: https://pubmed.ncbi.nlm.nih.gov/23782513/
- CECMED: registration entry and summary of product characteristics for CIMAher (nimotuzumab) (Spanish): https://www.cecmed.cu/registro/rcp/biologicos/cimaherr-nimotuzumab

## Connected records

- institutions: [National Coordinating Centre of Clinical Trials, Cuba (CENCEC)](https://onco.cc/institutions/cencec-cuba/)
- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Nimotuzumab](https://onco.cc/drugs/nimotuzumab/)
- companies: [CIMAB](https://onco.cc/companies/cimab/)

---
JSON: https://onco.cc/api/v1/entities/paper-solomon-nimotuzumab-high-grade-glioma-bmc-cancer-2013.json